Mycobacterium tuberculosis, which causes tuberculosis, is the greatest single infectious cause of mortality worldwide, killing roughly two million people annually1. Estimates indicate that one-third of the world population is infected with latent M. tuberculosis2. The synergy between tuberculosis and the AIDS epidemic3,4,5, and the surge of multidrug-resistant clinical isolates of M. tuberculosis have reaffirmed tuberculosis as a primary public health threat. However, new antitubercular drugs with new mechanisms of action have not been developed in over thirty years. Here we report a series of compounds containing a nitroimidazopyran nucleus that possess antitubercular activity. After activation by a mechanism dependent on M. tuberculosis F420 cofactor, nitroimidazopyrans inhibited the synthesis of protein and cell wall lipid. In contrast to current antitubercular drugs, nitroimidazopyrans exhibited bactericidal activity against both replicating and static M. tuberculosis. Lead compound PA-824 showed potent bactericidal activity against multidrug-resistant M. tuberculosis and promising oral activity in animal infection models. We conclude that nitroimidazopyrans offer the practical qualities of a small molecule with the potential for the treatment of tuberculosis.
This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $3.90 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Dye, C., Scheele, S., Dolin, P., Pathania, V. & Raviglione, M. C. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. J. Am. Med. Ass. 282, 677–686 (1999).
Bloom, B. R. & Small, P. M. The evolving relation between humans and Mycobacterium tuberculosis. N. Engl. J. Med. 338, 677–678 (1998).
Kaufman, S. & van Embden, J. Tuberculosis: a neglected disease strikes back. Trends Microbiol. 1, 2– 5 (1993).
Bloom, B. R. & Murray, C. J. Tuberculosis: commentary on a reemergent killer. Science 257, 1055– 1064 (1992).
Fischl, M. A. et al. Clinical presentation and outcome of patients with HIV infection and tuberculosis caused by multiple-drug-resistant bacilli. Ann. Int. Med. 117, 184–190 ( 1992).
Agrawal, K. C. et al. Potential radiosensitizing agents. Dinitroimidazoles. J. Med. Chem. 22, 593–586 (1979).
Nagarajan, K., Shankar, R. G., Rajappa, S., Shenoy, S. J. & Costa-Pereira, R. Nitroimidazoles XXI 2,3-dihydro-6-nitroimidazo [2,1-b] oxazoles with antitubercular activity. Eur. J. Med. Chem. 24, 631–633 ( 1989).
Walsh, J. S. et al. Structural alterations that differentially affect the mutagenic and antitrichomonal activities of 5-nitroimidazoles. J. Med. Chem. 30, 150–156 ( 1987).
Ashtekar, D. R. et al. In vitro and in vivo activities of the nitroimidazole CGI 17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 37, 183–186 ( 1993).
Wayne, L. G. & Sramek, H. A. Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 38, 2054–2054 (1994).
Hickey, M. J. et al. Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob. Agents Chemother. 40, 400– 407 (1996).
Yuan, Y. & Barry, C. E. A common mechanism for the biosynthesis of methoxy and cyclopropyl mycolic acids in Mycobacterium tuberculosis. Proc. Natl Acad. Sci. USA 93, 12828– 12833 (1996).
Samuelson, J. Why metronidazole is active against both bacteria and parasites. Antimicrob. Agents Chemother. 43, 1533–1541 ( 1999).
Edwards, D. I. Mechanism of antimicrobial action of metronidazole. J. Antibicrob. Chemother. 5, 499–502 (1979).
Lisitsyn, N. & Lisitsyn, N. W. M. Cloning the differences between two complex genomes. Science 259, 946– 951 (1993).
Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537–544 (1998).
Purwantini, E. & Daniels, L. Purification of a novel coenzyme F420-dependent glucose-6-phosphate dehydrogenase from Mycobacterium smegmatis. J. Bacteriol. 178, 2861–2866 (1996).
Purwantini, E. & Daniels, L. Molecular analysis of the gene encoding F420-dependent glucose-6-phosphate dehydrogenase from Mycobacterium smegmatis. J. Bacteriol. 180, 2212–2219 (1998).
Barry, C. E. et al. Mycolic acids: structure, biosynthesis and physiological functions. Prog. Lipid Res. 37, 143– 179 (1998).
Yuan, Y., Zhu, Y., Crane, D. D. & Barry, C. E. The effect of oxygenated mycolic acid composition on cell wall function and macrophage growth in Mycobacterium tuberculosis. Mol. Microbiol. 29, 1449–1458 (1998).
Holt, J. G., Krieg, N. R., Sneath, P. H. A., Staley, J. T. & Williams, S. T. in Bergey's Manual of Determinative Bacteriology 9th edn 597 (Williams and Wilkins, Baltimore, 1994).
Arain, T. M., Resconi, A. E., Hickey, M. J. & Stover, C. K. Bioluminescence screening in vitro (Bio-Siv) assays for high-volume antimycobacterial drug discovery. Antimicrob. Agents Chemother. 40, 1536–1541 ( 1996).
van Embden, J. D. et al. Strain identification of Mycobacterium tuberculosis by DNA fingerprinting: recommendations for a standardized methodology. J. Clin. Microbiol. 31, 406–409 (1993).
Smith, D. W., Balasubramanian, V. & Wiegeshaus, E. H. A guinea pig model of experimental airborne tuberculosis for the evaluation of the response to chemotherapy: the effect on bacilli in the initial phase of treatment. Tubercle 72, 223–231 (1991).
About this article
Cite this article
Stover, C., Warrener, P., VanDevanter, D. et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature 405, 962–966 (2000). https://doi.org/10.1038/35016103
Medicinal Chemistry Research (2021)
The Journal of Antibiotics (2020)
Drugs & Therapy Perspectives (2020)
The Journal of Antibiotics (2019)